The aim of this study is to assess the impact of ketamine on aesthetic perception and processing. This study assesses the role of these effects in facilitating ketamine's antidepressant properties, with a focus on anhedonia. To address this aim, 25 patients with major depressive disorder and 35 healthy controls will be assessed twice with magnetic resonance imaging, once after administration of intravenous ketamine (subanesthetic dose) and once after administration of placebo.This study has a single-center, placebo-controlled, cross-over study design. During MRI, structural, resting state, and functional imaging will be performed. Functional imaging will comprise aesthetic processing, reward, and sexual arousal paradigms. In addition, various neuropsychological scales assessing depressive symptoms, anhedonia, and aesthetic processing will be performed. Eligibility for participation will be assessed during a screening visit, a follow up visit will end study participation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
60
0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study
0.9% NaCl
Medical University of Vienna
Vienna, Austria
RECRUITINGBOLD signal assessed with fMRI during aesthetic paradigm
Difference in Blood Oxygen Level Dependent (BOLD) signal assessed with functional magnetic resonance imaging (fMRI) between ketamine and placebo condition during an aesthetic processing task
Time frame: Change from baseline to up to 4 weeks
BOLD signal assessed with fMRI during reward paradigm
Difference in Blood Oxygen Level Dependent (BOLD) signal assessed with functional magnetic resonance imaging (fMRI) between ketamine and placebo condition during a reward processing task
Time frame: Change from baseline to up to 4 weeks
BOLD signal assessed with fMRI during sexual arousal paradigm
Difference in Blood Oxygen Level Dependent (BOLD) signal assessed with functional magnetic resonance imaging (fMRI) between ketamine and placebo condition during a sexual arousal paradigm
Time frame: Change from baseline to up to 4 weeks
Levels of pleasantness assessed during aesthetic fMRI task
Level of pleasantness (Numbered scale) of aesthetic stimuli during aesthetic paradigm task
Time frame: Change from baseline to up to 4 weeks
Number of of chills assessed during aesthetic fMRI task
Number of chills in response to aesthetic stimuli during aesthetic paradigm task
Time frame: Change from baseline to up to 4 weeks
BOLD signal assessed with fMRI during resting state
Difference in Blood Oxygen Level Dependent (BOLD) signal assessed with functional magnetic resonance imaging (fMRI) between ketamine and placebo condition during resting state
Time frame: Change from baseline to up to 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.